

**TARGET-ORIENTED APPROACH TO DIAGNOSIS AND PHARMACOTHERAPY OF  
NASH: A DIALOGUE BETWEEN ACADEMIA AND INDUSTRY  
9-11 NOVEMBER 2017  
ROME, ITALY**

**SCIENTIFIC ORGANISING COMMITTEE:**

Ali Canbay, *Germany*

Claus Hellerbrand, *Germany*

Wing-Kin Syn, *United States*

Michael Trauner, *Austria*

---

**PRELIMINARY PROGRAMME**

**DAY 1 – Thursday 9 November 2017**

13:55 – 14:00      Welcome and introductory remarks  
Michael Trauner, *Austria*

14:00 – 14:30      **State-of-the-Art lecture**  
Unmet needs in understanding pathogenesis and management of  
NAFLD and NASH  
Vlad Ratziu, *France*

**HEPATIC LIPID METABOLISM AND LIPOTOXICITY AS PROGNOSTIC / THERAPEUTIC  
TARGET**

**Chairs:**              Michael Trauner, *Austria*  
Christopher Day, *United Kingdom*

- 14:30 – 14:55 Benefits/perils of promoting lipid combustion or inhibition of lipogenesis (DGAT, SCD, ANGPTL-3 inhibitors) in counteracting lipotoxicity  
Leanne Hodson, *United Kingdom*
- 14:55 – 15:20 PNPLA3 and other genetic markers (TM6SF2) for risk stratification  
Quentin Mark Anstee, *United Kingdom*
- 15:20 – 15:45 PPAR alpha and/or delta as pharmacological target (including discussion of FGF-2I (PPAR downstream target) and brown/beige fat as PPAR/FGF2I target)  
Bart Staels, *France*
- 15:45 – 16:10 CAP, MR and MR spectroscopy– does hepatic lipid content/composition matter  
Manuel Romero-Gomez, *Spain*
- 16:10 – 16:30 *Coffee break and ePoster session I*

## INSULIN RESISTANCE, INSULIN AND HORMONAL SIGNALING

**Chairs:** Helena Cortez-Pinto, *Portugal*  
Philip Newsome, *United Kingdom*

- 16:30 – 16:55 Academic overview: What dissociates steatosis and insulin resistance in humans?  
Hannele Yki-Järvinen, *Finland*
- 15:55 – 17:20 Insulin sensitizers (metformin, TZDs/PPAR gamma) – in or out (including novel insulin, glucagon, GLP-I fusion mimetics?)  
Christopher Byrne, *United Kingdom*
- 17:20 – 17:45 GLP-I receptor agonists in diabetes and obesity: A potential in NASH?  
Lotte Knudsen, *Denmark*

17:45 – 18:10 Vitamin D, thyroid function (the obvious and neglected; including Liver-Directed Thyroid Hormone Receptor- $\beta$  (THR- $\beta$ ) agonists  
Rebecca Taub, *United States*

18:10 – 18:40 *Coffee break and ePoster session 2*

### **OXIDATIVE STRESS, ER STRESS, MITOCHONDRIAL DYSFUNCTION**

**Chairs:** Ali Canbay, *Germany*  
Luca Valenti, *Italy*

18:40 – 19:05 Academic overview  
Christian Trautwein, *Germany*

19:05 – 19:30 Targeting oxidative stress and ER stress: more than Vitamin E and UDCA  
Gökhan Hotamisligil, *United States*

19:30 – 19:55 Risk and benefit of pharmacological stimulation of mitochondrial (dys)function  
Michael Roden, *Germany*

20:00 – 21:00 *Cocktail reception and ePoster session 3*

### **DAY 2 – Friday 10 November 2017**

### **INFLAMMATION, ADAPTIVE AND INNATE IMMUNITY IN NASH**

**Chairs:** Frank Tacke, *Germany*  
Win-Kin Syn, *United States*

- 08:30 – 08:55      Academic overview  
Frank Tacke, *Germany*
- 08:55 – 09:20      Industry perspective – inhibitors of CCR2 and 5  
Eric Lefebvre, *United States*
- 09:20 – 09:45      Oral immune therapy for NASH: A new class of drugs that target the  
gut immune system  
Yaron Ilan, *Israel*
- 09:45 – 10:10      Role of Inflammasomes in NAFLD  
Fabio Marra, *Italy*
- 10:10 – 10:35      VAP-I inhibitors  
Joerg Rippmann, *Germany*
- 10:35 – 10:55      *Coffee break and ePoster session 4*

#### **APOPTOSIS, MICROPARTICLES**

**Chairs:**                      Jose Fernandez-Checa, *Spain*  
Helen Reeves, *United Kingdom*

- 10:55 – 11:20      Academic overview  
Ali Canbay, *Germany*
- 11:20 – 11:45      Caspase inhibitors: academic clinical  
Jose Fernandez-Checa, *Spain*
- 11:45 – 12:10      Microparticles as biomarker  
Ariel Feldstein, *United States*
- 12:10 – 12:35      Keratins as biomarkers  
Heike Bantel, *Germany*
- 12:35 – 14:00      *Lunch and Sympo (TBC)*

## **BILE ACIDS, BILE ACID SIGNALING: BILE ACIDS AS PROGNOSTIC SIGNATURE IN NASH**

- Chairs:** Cecilia Rodrigues, *Portugal*  
Michael Trauner, *Austria*
- 14:00 – 14:25** Academic overview  
Michael Trauner, *Austria*
- 14:25 – 14:50** Bile acids as prognostic signature in NASH  
Marco Arrese, *Chile*
- 14:50 – 15:15** FXR – steroidal agonists  
Luciano Adorini, *Italy*
- 15:15 – 15:40** FXR – non- steroidal agonists  
Nikolai Naoumov, *Switzerland*
- 15:40 – 16:05** FGF-19 (FXR downstream target)  
Matias Avila, *Spain*
- 16:05 – 16:30** ASBT inhibitors  
Hanns-Ulrich Marschall, *Sweden*
- 16:30 – 17:00** *Coffee break and ePoster session 6*

## **GUT MICROBIOTA**

- Chairs:** Tom Karlsen, *Norway*  
Bernd Schnabl, *United States*
- 17:10 – 17:25** Academic overview  
Bernd Schnabl, *United States*
- 17:25 – 17:50** Microbiome as prognostic signature  
Jacques Amar, *France*

17:50 – 18:15      Microbiota and FXR signaling in NAFLD and obesity, to induce or not to induce – that is the question  
Annika Wahlström, *Sweden*

18:15 – 18:40      Probiotic interventions  
Vanessa Stadlbauer-Köllner, *Austria*

## DAY 3 – Saturday 11 November 2017

### CARCINOGENESIS

**Chairs:**              Jean-François Dufour, *Switzerland*  
Claus Hellerbrand, *Germany*

08:30 – 08:55      Academic overview: NASH as fertile soil for HCC, including challenge of pre-cirrhotic HCC  
Jean-François Dufour, *Switzerland*

08:55 – 09:20      MiRNA as biomarker and target  
Cecilia Rodrigues, *Portugal*

09:20 – 09:45      Circulating tumour (stem) cells and liquid biopsy  
Mathias Heikenwälder, *Germany*

09:45 – 10:10      Alcohol and nutrition in NAFLD progression to cancer  
Claus Hellerbrand, *Germany*

10:10 – 10:35      Liver histology for biomarker and target discovery  
Peter Schirmacher, *Germany*

10:35 – 11:00      *Coffee break and ePoster session 7*

## FIBROSIS

### Chairs:

**Ali Canbay, *Germany***  
**Claus Hellerbrand, *Germany***  
**Wing-Kin Syn, *United States***  
**Michael Trauner, *Austria***

**11:00 – 11:25**

**Academic overview**  
**Massimo Pinzani, *United Kingdom***

**11:25 – 11:50**

**Fibrosis as prognostically relevant signature: – do we have to care about differentiating NASH from NAFL (or just fibrosis)**  
**Mattias Ekstedt, *Sweden***

**11:50 – 12:15**

**How to non-invasively assess fibrosis (serum, transient elastography, MRE)**  
**Laurent Castera, *France***

**12:15 – 12:40**

**Targeting liver fibrosis: have we been listening to this song for too long now? (industry perspective)**  
**Matthias Ocker, *Germany***

**12:40 – 13:05**

**LOXL-2: single target (fibrosis resolution) or key for combination therapies?**  
**Robert Myers, *United States***

**13:05 – 13:30**

**What is needed for drug approval? (Regulatory readouts from fibrosis studies)**  
**Arun Sanyal, *United States***

**13:30 – 13:45**

***Concluding Remarks***